VJHemOnc is committed to improving our service to you

EBMT 2020 | Results of ALLRE08 PETHEMA

VJHemOnc is committed to improving our service to you

Josep-Maria Ribera

Josep M. Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the results of the ALLRE08 PETHEMA trial, evaluating young patients with standard-risk acute lymphoblastic leukemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Transcript (edited for clarity)

This trial was directed for patients with adolescent and young adult patients and up to the age of 30 year, with standard risk ALL.

So, these patients were treated with a full pediatric trial with the key elements: induction, consolidation, reinduction and maintenance therapy. And this trial was also MRD didactic.

So, in order that those patients who had a poor MRD response after induction were moved quickly to a high risk trial in order to increase the possibility of a cure for these patients being treated with intensified therapy, followed by allogeneic transplantation...

This trial was directed for patients with adolescent and young adult patients and up to the age of 30 year, with standard risk ALL.

So, these patients were treated with a full pediatric trial with the key elements: induction, consolidation, reinduction and maintenance therapy. And this trial was also MRD didactic.

So, in order that those patients who had a poor MRD response after induction were moved quickly to a high risk trial in order to increase the possibility of a cure for these patients being treated with intensified therapy, followed by allogeneic transplantation.

And those patients with a standard MRD response throughout the trial were not transplanted. And the main results of these trials was 70% of event-free survival for five years.

And when we compared those patients with good MRD response and treated with chemotherapy, without transplantation, with those who were moved to a high-risk protocol because of poor MRD response, the difference was not statistically significant, although the patients who were treated without transplantation fared better than those who will need transplantation because of poor MRD response. But in any case, the difference was not statistically significant.

So, the main message is that full pediatric trial for adolescents and young adults with standard risk ALL is feasible. Most of these patients have a good MRD response and were not transplanted and achieved event-free survival of 60 to 70%.

And the third message is that those patients who did not achieve a good MRD status and were moved to a high-risk transplantation could be successfully rescued with this approach. These were the main messages from this trial.

 

Read more...

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter